(Q41046855)

26 September 2017

title

Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products (English)

1 reference

26 September 2017

0 references

1 reference

Pride MW

1

1 reference

26 September 2017

Bailey CR

series ordinal

2

1 reference

26 September 2017

Muchmore E

series ordinal

3

1 reference

26 September 2017

Thanavala Y

series ordinal

4

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

26 September 2017

1 reference

26 September 2017

volume

16

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

543-550

1 reference

Long-term follow-up of chronic active hepatitis of moderate severity

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Virus-like particles in serum of patients with Australia-antigen-associated hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Genetic prediction of nonresponse to hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

The cellular basis for lack of antibody response to hepatitis B vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

The immune response to hepatitis B vaccine in humans: inheritance patterns in families

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Hepatitis B vaccination in chronic alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Development and production aspects of a recombinant yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

A self-associating hepatitis B surface antigen-derived peptide that is immunogenic in alum

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Mimicry of the a determinant of hepatitis B surface antigen by an antiidiotypic antibody. I. Evaluation in hepatitis B surface antigen responder and nonresponder strains

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Stable expression of the hepatitis B virus surface antigen containing pre-S2 protein in mouse cells using a bovine papillomavirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Expression of hepatitis B virus surface antigen containing the pre-S region in mammalian cell culture system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Immunofluorescent technique for the detection of monoclonal internal image anti-idiotypic antibodies of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Interaction between various polymerized human albumins and hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

Three-week hepatitis B vaccination provides protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900242-9

7 January 2021

10.1016/S0264-410X(97)00242-9

Identifiers

DOI

1 reference

26 September 2017

1 reference